Scgb3a2 as a growth factor and anti-apoptotic agent
AssigneesServices, The United States of America, as represented by the Secretary, Department of Health and Human
InventorsShioko Kimura, Reiko Kurotani
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.
Claims17
A method of inhibiting or reducing lung damage caused by an anti-cancer agent in a subject, comprising:
- administering a therapeutically effective amount of murine or human SCGB3A2 to a murine or human subject, wherein the subject is being treated with or will be treated with an anti-cancer agent, thereby inhibiting lung damage caused by the anti-cancer agent.
Dependencies are inferred from the claim text.